HER2 became of interest as the first prioritized target as trans-(±)-kusunokinin because HER2 was suggested as the challenging targets for breast cancer therapy [23], due to its drug resistance, cross-resistance to other HER2-targeted drugs [24,25], and drug toxicity [26,27]. Here, ERBB2 is linked to breast cancer.